Asif Ali - 29 Feb 2024 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Signature
/s/ Matthew Gosling, Attorney-in-Fact for Asif Ali
Issuer symbol
PTGX
Transactions as of
29 Feb 2024
Net transactions value
-$618,325
Form type
4
Filing time
01 Mar 2024, 20:45:27 UTC
Previous filing
18 Jan 2024
Next filing
19 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Sale $240,288 -7,850 -16% $30.61 42,734 29 Feb 2024 Direct F1
transaction PTGX Common Stock Sale $64,759 -2,089 -4.9% $31.00 40,645 29 Feb 2024 Direct
transaction PTGX Common Stock Options Exercise $146,040 +12,000 +30% $12.17 52,645 01 Mar 2024 Direct
transaction PTGX Common Stock Sale $386,640 -12,000 -23% $32.22 40,645 01 Mar 2024 Direct F2
transaction PTGX Common Stock Sale $72,678 -2,248 -5.5% $32.33 38,397 01 Mar 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -12,000 -19% $0.000000 51,750 01 Mar 2024 Common Stock 12,000 $12.17 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.57 to $30.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.17 to $32.31. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant.